New data demonstrates the value of regulatory data protection (RDP), and its impact on European competitiveness and patient access to medicines
New data from Copenhagen Economics shows that out of 53 countries – with and without RDP –patients in countries with RDP have three times higher availability of innovative medicines than those without, and significantly almost half of the difference in availability can be attributed to RDP.
Read more here.